Independent Financial Group LLC Purchases Shares of 143,667 Healthpeak Properties, Inc. $DOC

Independent Financial Group LLC purchased a new stake in shares of Healthpeak Properties, Inc. (NYSE:DOC) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 143,667 shares of the real estate investment trust’s stock, valued at approximately $2,360,000.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its position in shares of Healthpeak Properties by 1.8% in the third quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock worth $947,889,000 after buying an additional 895,460 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Healthpeak Properties by 8.6% during the fourth quarter. JPMorgan Chase & Co. now owns 30,674,812 shares of the real estate investment trust’s stock valued at $493,251,000 after buying an additional 2,438,278 shares during the period. Fuller & Thaler Asset Management Inc. grew its position in Healthpeak Properties by 19.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock worth $476,744,000 after buying an additional 4,776,056 shares in the last quarter. Geode Capital Management LLC grew its position in Healthpeak Properties by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 19,534,041 shares of the real estate investment trust’s stock worth $312,959,000 after buying an additional 123,274 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Healthpeak Properties by 9.9% in the 4th quarter. Invesco Ltd. now owns 18,298,776 shares of the real estate investment trust’s stock worth $294,244,000 after acquiring an additional 1,648,012 shares during the last quarter. Institutional investors own 93.57% of the company’s stock.

Healthpeak Properties Price Performance

DOC opened at $22.52 on Friday. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $15.53 billion, a P/E ratio of 70.39, a PEG ratio of 3.50 and a beta of 1.02. The stock has a 50-day moving average price of $20.47 and a 200-day moving average price of $18.24. Healthpeak Properties, Inc. has a 12-month low of $15.70 and a 12-month high of $22.62.

Healthpeak Properties (NYSE:DOC) last announced its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $752.95 million for the quarter, compared to analysts’ expectations of $694.59 million. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.Healthpeak Properties’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Equities analysts predict that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current fiscal year.

Healthpeak Properties Dividend Announcement

The firm also recently declared a monthly dividend, which will be paid on Friday, September 25th. Shareholders of record on Monday, September 14th will be given a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a yield of 5.4%. The ex-dividend date is Monday, September 14th. Healthpeak Properties’s dividend payout ratio (DPR) is presently 381.25%.

Insider Activity at Healthpeak Properties

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the transaction, the insider directly owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wells Fargo & Company raised their price target on Healthpeak Properties from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Healthpeak Properties from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Evercore downgraded shares of Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price on the stock. in a research note on Monday, May 11th. Finally, Robert W. Baird lifted their target price on shares of Healthpeak Properties from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.62.

Healthpeak Properties Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.